Cortés-López PN, Vega-Sánchez D, Juárez-Durán ER, Arenas R

Language: Spanish
References: 23
Page: 7-12
PDF size: 352.60 Kb.

ABSTRACT

Background: patients with diabetes are more susceptible to the development of mycoses due to alterations in cellular immunity.
Objective: to analyze mycoses associated with diabetes mellitus at the Mycology Section of the Dr. Manuel Gea González General Hospital from 2012 to 2022.
Methodology: retrospective and observational study. 810 subjects with diabetes and diagnosis of a mycoses, confirmed by a mycological test were included.
Resultados: dermatophytoses mainly onychomycosis and tinea pedis were the most frequent. Trichophyton rubrum and Candida spp. were the main etiological agents. In subcutaneous mycoses there were three cases of chromoblastomycosis and one case of sporotrichosis. Also 18 cases of mucormycosis were found and, the most isolated agent was Rhizopus spp.
Comm ent: the high frequency of mycoses found in this report, highlights the importance of their clinical identification, and the need of mycological tests to confirm the diagnosis.

REFERENCES

1. Davies M, Roda V, Collins B et al., Management of hyperglycemiain type 2 diabetes, 2022. A consensus report by theAmerican Diabetes Association (ada) and the European Associationfor the Study of Diabetes (easd), Diabetes Care 2022;45(11):2753-86.

2. Instituto Nacional de Estadística y Geografía (inegi), Estadísticasa propósito del Día Mundial de la Diabetes, datos nacionales,comunicado de prensa: 645/21;2021. Disponible en: https://www.inegi.org.mx/contenidos/saladeprensa/aproposito/2021/EAP_Diabetes2021.pdf.

3. Basto A, López N, Rojas R et al., Prevalencia de prediabetes ydiabetes en México. Ensanut 2022, Salud Pública Mex 2023;65:S163-8.

4. ElSayed N, Aleppo G, Aroda V et al., 2. Classification and diagnosisof diabetes: standards of care in diabetes 2023, DiabetesCare 2023; 46(Suppl 1):S19-40.

5. Berbudi A, Rahmadika N, Tjahjadi AI et al., Type 2 diabetes andits impact on the immune system, Curr Diabetes Rev 2020;16(5):442-9.

6. Martínez N, Ketheesan N, Martens G et al., Defects in early cellrecruitment contribute to the increased susceptibility to respiratoryKlebsiella pneumoniae infection in diabetic mice, MicrobesInfect 2016; 18(10):649-55.

7. Daryabor G, Atashzar M, Kabelitz D, Meri S et al., The effects oftype 2 diabetes mellitus on organ metabolism and the immunesystem, Front Immunol 2020; 11:1582.

8. Wang X, Ota N, Manzanillo P et al., Interleukin-22 alleviatesmetabolic disorders and restores mucosal immunity in diabetes,Nature 2014; 514(7521):237-41.

9. Frías de León M, Rosas de Paz E, Arenas R et al., Identificationof Aspergillus tubingensis in a primary skin infection, J MycolMed 2018; 28(2):274-8.

10. Saunte D, Holgersen J, Haedersdal M et al., Prevalence of toenailonychomycosis in diabetic patients, Acta Derm Venereol2006; 86:425-8.

11. Dogra S, Kumar B, Bhansali A et al., Epidemiology of onychomycosisin patients with diabetes mellitus in India, Int J Dermatol2002; 41:647-51.

12. Rich P, Onychomycosis and tinea pedis in patients with diabetes,J Am Acad Dermatol 2000; 43:S130-4.

13. Alrauosh H, Ababneh A, Bakri F et al., Prevalence and associatedfactors of toenail onychomycosis among patients withdiabetes in Jordan, Curr Diabetes Rev 2023; 10:2174.

14. Segundo L, Sierra K y Arenas R, Onicomicosis en la poblacióndiabética: importancia de las complicaciones, tratamiento y prevención,Dermatologíacmq 2021; 19(3):289-94.

15. Fuentes A y Chimal M, La importancia de la piel en la diabetesmellitus, Medicina e Investigación 2015; 3(1):61-73

16. García L, Richard N, Pérez M et al., Frecuencia de micosis superficiales:estudio comparativo en pacientes diabéticos tipo2 y en individuos no diabéticos, Investigación Clínica 2005;46(1):65-74.

17. Arenas R, Micología médica ilustrada, México, McGraw-Hill,2019, pp. 67-99.

18. Hernández A, Camerino A, Colín Y et al., Micosis pulmonaresen pacientes con diabetes mellitus. Características clínicas yfactores de riesgo, Rev Iberoam Micol 2020; 37(2):53-7.

19. Vazheva G, Zisova L, Becheva E et al., In search of dermatophytes:frequency and etiology of fungal infections in patientswith and without diabetes mellitus, Folia Med (Plovdiv) 2022;64(6):922-31.

20. Steinbrink J y Miceli M, Mucormycosis, Infect Dis Clin NorthAm 2021; 35(2):435-52. doi: 10.1016/j.idc.2021.03.009.

21. Anand V, Alemar G y Griswold J, Intracranial complications ofmucormycosis: an experimental model and clinical review, Laryngoscope1992; 102:656-62.

22. Sengupta I y Nayak T, Coincidence or reality behind mucormycosis,diabetes mellitus and covid-19 association: a systematicreview, J Mycol Med 2022; 32(3):101257.

23. Satish D, Joy D y Ross A, Mucormycosis coinfection associatedwith global covid-19: a case series from India, Int J OtorhinolaryngolHead Neck Surg 2021; 7:815.